Newsroom

Title
EvergreenHealth Launches COVID-19 Antibody Clinical Trial
Date
09/15/2020
Article

Kirkland, Wash. – EvergreenHealth announced that the health system has partnered with Eli Lilly and Company to study a new drug to treat patients with COVID-19. The BLAZE-1 Study is designed to look at the safety and efficacy of treating adults who have recently tested positive for COVID-19, and who are not hospitalized, with the investigational study drug, LY-Co-V555. EvergreenHealth is the only health system in Washington state to serve as a trial site for the BLAZE-1 Study.

LY-Co-V555 is an antibody therapy engineered from one of the first individuals to recover from COVID-19, which may help newly diagnosed patients’ immune systems clear the SARS-CoV-2 virus more quickly. Laboratory studies have shown that LY-CoV555 binds with high affinity to the SARS-CoV-2 virus and neutralizes its ability to infect cells and replicate.

“Research is essential to finding the most effective methods for treating and preventing a novel virus, such as SARS-CoV-2, and we feel fortunate to bring this clinical trial to our patients and community to help this important work progress. We look forward to partnering with volunteer participants who have been diagnosed with COVID-19, to explore the possibilities of a potential treatment,” said Jeff Tomlin, MD, EvergreenHealth CEO.

To be eligible for the BLAZE-1 Study, participants must have tested positive for SARS-CoV-2 infection within three days prior to the study drug infusion, and have one or more mild or moderate COVID-19 symptoms, including: fever, cough, sore throat, headache, muscle pain, nausea, abdominal pain, diarrhea, or shortness of breath when active. They also cannot be pregnant or breastfeeding, or have other serious medical conditions besides COVID-19.

If an individual is eligible and decides to participate in the study, the research team at EvergreenHealth will perform specific tests and procedures to monitor the patient’s health and how their body reacts to the LY-CoV555 antibody treatment. These tests and procedures include physical exams, vital sign measurements, blood samples, and nasopharyngeal swabs to measure levels of virus.

The study drug is being compared to a placebo, and both the study drug and the placebo will be administered as a single-dose intravenous (IV) infusion. Participants will be randomly selected to receive the placebo or the study drug on Day 1, and will then participate in follow-up assessments over a 12-week period.

“We are thrilled to partner with Eli Lilly on the innovative BLAZE-1 Study,” said Chad Crystal, MD, Principal Investigator. “Hosting this clinical trial gives us the opportunity to not only potentially protect those most at risk of severe illness, but it also gives us the chance to impact the health and well-being of those right here in our community and beyond. As frontline care clinicians, we know how important it is to rally together to find a safe, effective treatment for COVID-19, and we’re proud to help advance those efforts in any way we can.”

Please call 425.650.0019 to be screened for participation and to speak with an EvergreenHealth physician about next steps for joining the study. You can also learn more at www.evergreenhealth.com/blaze-study

###

About EvergreenHealth
EvergreenHealth is an integrated health care system serving nearly one million residents in King and Snohomish counties with a breadth of services and programs that are among the most comprehensive in the region. Formed as a public hospital district in 1972, EvergreenHealth includes a 318-bed acute care medical center in Kirkland and a 72-bed hospital, EvergreenHealth Monroe, which is an accredited, full-service public hospital district established in 1960 in Monroe, Washington. The system also includes a network of 13 primary care practices, five urgent care centers, more than two dozen specialty care practices, extensive home care and hospice services, and 24/7 emergency care from its Kirkland, Monroe and Redmond locations.

EvergreenHealth remains committed to its purpose to enrich the health and well-being of the community by providing clinical excellence in more than 80 specialties and through extensive community health outreach and education programs, anchored by the 24/7 EvergreenHealth Nurse Navigator & Healthline.
The health system is consistently named as one of Healthgrades America’s 100 Best Hospitals and it is one of only 407 hospitals nationwide to hold a 5-Star Overall Rating from the Centers for Medicaid & Medicare Services (CMS). Learn more at www.evergreenhealth.com


MEDIA CONTACTS:

Kayse Dahl
EvergreenHealth
425.899.1855
KLDahl@evergreenhealthcare.org 

Kristi Herriott
Firmani + Associates Inc.
206.443.9357
kristi@firmani.com